Novo Nordisk chief financial officer Karsten Munk Knudsen said on Wednesday the company was aware of reports of 10 deaths and ...

Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have ...

Wegovy (semaglutide), a glucagon-like peptide-1 (GLP-1) receptor agonist, was first approved by the Food and Drug Administration ... provides to narrow down our list even further.

After years of shortages, the Food and Drug Administration (FDA) has now listed Novo Nordisk’s blockbuster diabetes and ...

Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have ...

Unable to keep food down, Barber’s weight dropped by more ... and her medical records list her gastroparesis as “idiopathic”—that is, without a known cause. But Barber feels certain ...

Shares of AstraZeneca dropped more than 7% yesterday after the Chinese publication Yicai Global reported that dozens of ...

The FDA became aware of the problem after a patient submitted a complaint to the regulator that a vial of semaglutide from ...

There's buzz around certain type 2 diabetes drugs, which not only help regulate blood sugar but can also lead to significant ...

Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have ...

These drugs are collectively known as GLP-1 agonists because they mimic the body’s natural hormone GLP-1, which regulates ...